Simvastatin Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition
Simvastatin Price Trend, Index and Forecast
Track the latest insights on simvastatin price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Simvastatin Prices Outlook Q4 2025
- USA: USD 243,402/MT
- China: USD 245,779/MT
- India: USD 252,583/MT
- Germany: USD 264,043/MT
- Japan: USD 328,988/MT
Simvastatin Price Chart
Get real-time access to monthly/quarterly/yearly prices Request Sample
During the fourth quarter of 2025, the simvastatin prices in the USA reached 243,402 USD/MT in December. The market saw a decline due to balanced inventory levels among pharmaceutical producers and consistent domestic output. While sufficient availability of active pharmaceutical ingredients restrained upward pricing pressure, softer procurement from generic medicine manufacturers decreased spot market activity. Stable supply conditions were a result of distribution networks operating without significant disruptions.
During the fourth quarter of 2025, the simvastatin prices in China reached 245,779 USD/MT in December. Due to increased supply chain efficiency and enough production output, prices decreased. As pharmaceutical manufacturers kept up steady production rates, both local and international markets had comfortable stock availability. There was less pressure on suppliers to increase offers because export inquiries from foreign buyers remained modest. Additionally, continuous synthesis activities were supported by steady raw material access.
During the fourth quarter of 2025, the simvastatin prices in India reached 252,583 USD/MT in December. The market experienced a gradual price decline influenced by stable active pharmaceutical ingredient production and steady feedstock availability. Domestic pharmaceutical formulators adopted conservative procurement strategies, limiting bulk transactions. Export demand remained consistent but lacked strong upward momentum, which restricted price recovery. Manufacturing operations continued smoothly without significant logistical constraints, supporting balanced supply conditions.
During the fourth quarter of 2025, the simvastatin prices in Germany reached 264,043 USD/MT in December. The market reflected softening demand from pharmaceutical manufacturers, particularly within the generics segment. Adequate import availability from Asian producers ensured comfortable supply levels, limiting upward price adjustments. Distributors reported moderate restocking activity, primarily to maintain routine inventory thresholds rather than expand positions. Regulatory compliance and quality assurance processes remained stable, preventing supply disruptions.
During the fourth quarter of 2025, the simvastatin prices in Japan reached 328,988 USD/MT in December. The market observed a moderate price decrease influenced by steady import flows and stable domestic pharmaceutical production. Procurement activity from formulators remained measured, reflecting sufficient inventory coverage. Distribution channels operated efficiently, reducing the risk of supply bottlenecks. Importers benefited from consistent shipments from major exporting countries, which eased concerns regarding availability.
Simvastatin Prices Outlook Q3 2025
- USA: USD 257,052/MT
- China: USD 258,769/MT
- India: USD 261,310/MT
- Germany: USD 277,671/MT
- Japan: USD 345,503/MT
During the third quarter of 2025, the simvastatin prices in the USA reached 257,052 USD/MT in September. The market experienced a slight upward movement supported by steady procurement from generic drug manufacturers. Restocking activity improved during the quarter as pharmaceutical companies adjusted inventories in response to stable prescription demand. Supply conditions remained balanced, though moderate logistical expenses added marginal cost pressure.
During the third quarter of 2025, the simvastatin prices in China reached 258,769 USD/MT in September. Prices edged upward due to firm export demand and active procurement from overseas buyers. Manufacturers maintained stable production levels, yet consistent order inflow supported improved transaction volumes. Domestic pharmaceutical consumption remained steady, reinforcing market confidence. Supply chains functioned efficiently, although incremental operational expenses influenced pricing decisions.
During the third quarter of 2025, the simvastatin prices in India reached 261,310 USD/MT in September. The market recorded a marginal increase driven by steady export orders and healthy domestic pharmaceutical production. Manufacturers operated at stable utilization rates, while procurement from formulators remained consistent. Improved demand visibility encouraged suppliers to maintain firmer offers. Logistics and compliance costs exerted a moderate upward influence on transaction values.
During the third quarter of 2025, the simvastatin prices in Germany reached 277,671 USD/MT in September. The market observed slight price strengthening supported by steady pharmaceutical consumption and routine restocking activities. Import arrivals from Asia remained consistent, yet firm procurement from generics manufacturers sustained transactional momentum. Distribution networks operated without disruption, ensuring stable availability.
During the third quarter of 2025, the simvastatin prices in Japan reached 345,503 USD/MT in September. The market noted a slight increase influenced by steady import demand and stable domestic pharmaceutical production. Buyers maintained consistent procurement volumes to support routine medication supply. Import flows remained reliable, while competitive global offers limited excessive price escalation. Suppliers adjusted quotations marginally in response to balanced demand conditions.
Simvastatin Prices Outlook Q2 2025
- USA: USD 256,232/MT
- China: USD 258,227/MT
- India: USD 260,451/MT
- Germany: USD 276,730/MT
- Japan: USD 345,123/MT
During the second quarter of 2025, simvastatin prices in the USA reached 256,232 USD/MT in June. Simvastatin prices in the United States exhibited moderate stability during the second quarter of 2025, with slight fluctuations influenced by raw material costs and pharmaceutical-grade manufacturing inputs. Rising energy expenses and compliance with evolving regulatory standards contributed to incremental increases in production costs. Demand from the cardiovascular therapeutics segment remained consistent, supporting a balanced pricing environment. While logistics and import-related challenges had minimal impact on domestic supply, the market remained attentive to global supply chain dynamics. Overall, simvastatin prices reflected a stable outlook, closely aligned with cost trends and steady prescription volumes across healthcare channels.
During the second quarter of 2025, simvastatin prices in China reached 258,227 USD/MT in June. Simvastatin prices during the second quarter of 2025 remained relatively stable, supported by strong domestic production and consistent export demand. As one of the world’s largest simvastatin producers, China benefited from efficient supply chains and established processing infrastructure. While upstream costs, including energy and labor, saw minor fluctuations, they had a limited impact on overall pricing. Export volumes to North America and Europe remained robust, reinforcing steady industrial output. Demand from the food, beverage, and pharmaceutical sectors sustained price stability. Overall, the market reflected a firm outlook, driven by both domestic consumption and momentum in international trade.
During the second quarter of 2025, simvastatin prices in India reached 260,451 USD/MT in June. Simvastatin prices in India showed a marginal upward movement, primarily due to increasing costs of active pharmaceutical ingredients (APIs) and energy. As a major hub for generic drug production, India sustained strong domestic demand alongside robust export commitments. Local manufacturing remained steady, although global supply chain fluctuations and input costs exerted mild pressure on pricing. The overall market outlook remained stable, with prices reflecting a balance between manufacturing economics and demand from both public and private healthcare providers.
During the second quarter of 2025, simvastatin prices in Germany reached 276,730 USD/MT in June. Simvastatin prices experienced minor fluctuations, influenced by variable energy prices and tightening EU regulatory standards. Demand from hospitals and pharmacies remained consistent, driven by continued prescription of statin therapies. Manufacturing costs were moderately affected by labor and logistics adjustments, although supply availability was not significantly disrupted. The overall pricing landscape remained stable, with prices largely tracking operational costs and a consistent distribution across the country’s pharmaceutical network.
During the second quarter of 2025, simvastatin prices in Japan reached 345,123 USD/MT in June. Simvastatin prices remained largely steady, with limited fluctuations driven by modest shifts in raw material costs and pharmaceutical production inputs. Demand from the aging population and chronic disease management programs continued to support a stable consumption pattern. Government pricing controls and reimbursement mechanisms kept volatility low, while domestic supply chains operated efficiently. Overall, pricing trends remained aligned with the healthcare sector's needs and controlled manufacturing dynamics, thereby preserving market consistency throughout the quarter.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing simvastatin prices.
Europe Simvastatin Price Trend
Q4 2025:
In Europe, the simvastatin price index reflected a downward trajectory. The region experienced softer procurement from generic pharmaceutical manufacturers, while import availability from Asia remained stable. Adequate inventories across distribution hubs limited urgency in bulk purchasing. Regulatory compliance procedures proceeded without disruption, supporting uninterrupted supply. Competitive supplier quotations and measured restocking activity contributed to subdued trading momentum.
Q3 2025:
In Europe, the simvastatin price index showed a slight upward movement. Steady pharmaceutical demand from the generics segment and hospital supply chains supported consistent transactional activity across major economies. Routine restocking by distributors and contract manufacturers strengthened spot market engagement, particularly as buyers aimed to maintain optimal inventory thresholds ahead of seasonal demand patterns. Import flows from Asia remained consistent, ensuring balanced availability without creating oversupply pressure.
Q2 2025:
In Europe, simvastatin prices in the second quarter showed modest stabilization. While raw material and logistics costs remained influential, the market benefited from improved API supply chains and competitive generic presence. Demand from pharmaceutical distributors stayed consistent, supporting steady purchasing behavior. Price movements reflected cautious alignment with underlying cost trends—such as fermentation intermediate prices and inflation—while maintaining equilibrium amid regulated healthcare pricing environments. Overall, the European simvastatin market exhibited balanced conditions, characterized by stable procurement patterns and muted volatility.
This analysis can be extended to include detailed simvastatin price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Simvastatin Price Trend
Q4 2025:
In North America, the simvastatin price index recorded a decline. Stable domestic production and sufficient import arrivals ensured comfortable market availability. Pharmaceutical companies adopted cautious procurement strategies, reducing spot market transactions. Distribution efficiency and steady prescription demand maintained equilibrium in the supply chain. Competitive domestic supplier pricing further reinforced the softening trend. The region concluded the quarter with stable inventories and reduced upward pricing pressure.
Q3 2025:
In North America, the simvastatin price index registered marginal growth. Consistent domestic production from active pharmaceutical ingredient manufacturers supported reliable availability across the United States and Canada. Stable prescription demand for cholesterol management therapies encouraged formulators to maintain regular procurement cycles. Import arrivals complemented domestic output, preventing tightness while avoiding excess inventory accumulation. Suppliers responded to steady buyer engagement with moderate upward price revisions, reflecting improved transaction volumes.
Q2 2025:
In North America, simvastatin API import prices continued their upward momentum in Q2 2025, reflecting persistent global supply tightness and rising production costs. Reduced exports from major Asian suppliers, such as China and India, attributed to environmental regulations and higher input prices, exerted upward pressure. Meanwhile, demand from generic drug manufacturers and inventory restocking by distributors helped maintain price firmness. Although transportation expenses and currency fluctuations added some volatility, market sentiment remained strongly bullish, driven by constrained API availability and base demand strength throughout the quarter.
Specific simvastatin historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and Africa Simvastatin Price Trend
Q4 2025:
The report explores the simvastatin pricing trends and simvastatin price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
Q3 2025:
As per the simvastatin price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
In addition to region-wise data, information on simvastatin prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Simvastatin Price Trend
Q4 2025:
In the Asia Pacific, simvastatin prices declined due to ample production output and stable export demand. Manufacturing hubs maintained consistent operational rates, supporting adequate availability. Buyers across regional markets adopted conservative purchasing patterns, limiting transactional spikes. Competitive export quotations and efficient logistics reinforced the downward movement. Overall, steady supply conditions outweighed demand growth, leading to softer pricing.
Q3 2025:
In the Asia Pacific, simvastatin prices recorded mild gains during the third quarter of 2025. Strong export inquiries from North America and Europe supported manufacturing activity in leading production centers, reinforcing supplier confidence. Domestic pharmaceutical demand across major consuming countries remained stable, contributing to consistent order volumes. Producers maintained steady operating rates, while measured procurement of intermediates ensured uninterrupted output. In response to healthy order inflow and firm overseas demand, suppliers implemented modest price adjustments.
Q2 2025:
In the Asia-Pacific region, simvastatin prices remained largely stable, with a slight upward movement observed due to rising raw material and energy costs. Key markets, such as China and India, witnessed consistent demand from the generic pharmaceutical sector, supporting price stability. Local production capacity and export-oriented manufacturing helped balance regional supply. While minor fluctuations occurred due to currency variations and freight adjustments, the overall pricing environment reflected stable consumption trends and uninterrupted supply chains across the region's major pharmaceutical manufacturing hubs.
This simvastatin price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Simvastatin Price Trend
Q4 2025:
Latin America's simvastatin market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in simvastatin prices.
Q3 2025:
Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, simvastatin index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing simvastatin pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
SimvastatinPricing Report, Market Analysis, and News
IMARC's latest publication, “Simvastatin Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” presents a detailed examination of the simvastatin market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of simvastatin at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents a detailed simvastatin price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting simvastatin pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
Simvastatin Industry Analysis
The global simvastatin market size reached USD 10.1 Billion in 2025. By 2034, IMARC Group expects the market to reach USD 18.3 Billion, at a projected CAGR of 6.56% during 2026-2034. The market is primarily driven by the rising prevalence of cardiovascular disorders, expanding generic drug manufacturing, and increasing healthcare access across emerging economies.
Latest News and Developments:
- April 2025: Pharmazac launched Vasitimb, a combination therapy of ezetimibe and simvastatin, developed to support cardiovascular risk reduction and cholesterol management. The product is designed to reduce the risk of cardiovascular events in individuals with coronary heart disease (CHD) and those with a history of acute coronary syndrome (ACS), regardless of previous statin use.
Product Description
Simvastatin is a lipid lowering medication belonging to the statin class, primarily used to manage high cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It functions by inhibiting HMG CoA reductase, an enzyme involved in cholesterol synthesis in the liver, thereby lowering low density lipoprotein (LDL) cholesterol and triglycerides while modestly increasing high density lipoprotein (HDL) cholesterol. Simvastatin is widely prescribed for patients with hyperlipidemia, mixed dyslipidemia, and those at high risk for atherosclerotic cardiovascular disease.
Available in oral tablet form, simvastatin is typically taken once daily in the evening to align with the body’s natural cholesterol production cycle. It is commonly used alone or in combination with other lipid lowering agents such as ezetimibe. The drug is well tolerated in most patients, though potential side effects may include muscle pain, elevated liver enzymes, or, in rare cases, rhabdomyolysis. Simvastatin is a cornerstone of preventive cardiovascular therapy and remains an essential component in treatment guidelines worldwide. Its effectiveness, affordability, and long standing clinical use make it a key therapeutic option for managing cholesterol in the long term.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Simvastatin |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Simvastatin Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of simvastatin pricing, covering global and regional trends, spot prices at key ports, and a breakdown of FOB and CIF prices.
- The study examines factors affecting simvastatin price trend, including input costs, supply-demand shifts, and geopolitical impacts, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The simvastatin price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
.webp)
.webp){kind=logo}
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.